The research focused on children under five years of age, the group in which Campylobacter infections hit hardest. In this age band, diarrheal disease remains a major contributor to illness and death worldwide, and Campylobacter jejuni is frequently implicated alongside better-known culprits such as Salmonella and pathogenic Escherichia coli. Infection typically produces fever, abdominal cramps and bloody or watery diarrhea, and while most cases resolve on their own, severe episodes in malnourished or very young children can demand antibiotic treatment. That is precisely where resistance matters most: when clinicians in resource-limited hospitals must choose a drug empirically, without laboratory guidance, the local resistance landscape determines whether a child recovers quickly or deteriorates while ineffective therapy is administered.

To capture that landscape, the team collected stool samples from children under five presenting with diarrhea at six hospitals in Sana’a: Al Zahrawi Hospital, Algamohory Hospital, Alkowit Hospital, Al-Sabeen Hospital, Al-Thowraha Hospital and Ibn Khaldun Hospital. Samples were processed using culture methods optimized for Campylobacter, a fastidious organism that requires reduced oxygen, elevated carbon dioxide and selective media to grow reliably in the laboratory. Isolates were then subjected to antimicrobial susceptibility testing following standards set by the Clinical Laboratories Standards Institute, using Mueller-Hinton agar as the testing medium. In parallel, the researchers turned to molecular identification, sequencing the 16S rRNA gene, a slowly evolving component of the bacterial ribosome whose sequence serves as a molecular fingerprint for species-level identification, and constructing phylogenetic trees to compare their isolates with reference strains held in international databases.

The headline number from the study is a prevalence of 2.8 percent, with 11 of 389 children testing positive for Campylobacter jejuni. That figure may appear modest, but in the context of a single-city hospital survey of a pathogen that is notoriously difficult to culture, it represents a meaningful baseline for a country that has lacked systematic campylobacteriosis surveillance. The researchers also broke the results down by demographic and behavioral factors, and the patterns that emerged read like a map of transmission routes. Prevalence was higher among girls, at 3.5 percent, and among children aged 36 to 47 months, where it reached 6.2 percent. Children living in rural areas showed a prevalence of 3.5 percent, and infections clustered in the summer months, when 7.2 percent of sampled children in that season carried the bacterium.

The behavioral and environmental associations were particularly telling. Children who had contact with animals showed a prevalence of 4.3 percent, those who drank water from tap sources 5.6 percent, and those who consumed unpasteurized milk 3.7 percent. Each of these routes is well established in the international literature: Campylobacter jejuni colonizes the intestines of poultry, cattle and other animals without making them sick, contaminates water supplies through fecal shedding, and survives in raw milk, where even small doses can cause infection. In Yemen, where household animal keeping is common, municipal water treatment is inconsistent, and unpasteurized dairy remains part of traditional diets, these findings point to concrete, actionable interventions, from hand hygiene after handling animals to water treatment and safer food handling practices.

The antimicrobial results are the study’s most consequential contribution. The isolates displayed high resistance to macrolides, the drug class that includes erythromycin and azithromycin, which are internationally regarded as first-line treatments for severe campylobacteriosis, especially in children, for whom fluoroquinolones are often restricted. High resistance to aminoglycosides was also documented. Macrolide resistance in Campylobacter is particularly worrying because it arises through mutations in the ribosomal target and, once established in a population, tends to persist and spread. In many high-income surveillance systems, macrolide resistance in human Campylobacter isolates remains comparatively low, so the pattern observed in Sana’a signals a local treatment crisis: the drugs most likely to be prescribed for a sick child may simply not work.

By contrast, the isolates remained relatively susceptible to several other agents, with resistance recorded at 18.2 percent for ciprofloxacin, 27.3 percent for tetracycline and 27.3 percent for nalidixic acid. While these figures still represent substantial resistance by global standards, they suggest that, at present, some therapeutic options retain activity against Campylobacter jejuni circulating in Sana’a. The authors caution, however, that susceptibility patterns can shift rapidly under continued antibiotic pressure, and that fluoroquinolone resistance in Campylobacter has risen steeply in many parts of the world following the use of these agents in poultry production. Sustained local susceptibility testing, they argue, is essential to keep empirical treatment guidelines aligned with reality on the ground.

The molecular arm of the study added a layer of confidence that culture alone cannot provide. Sequencing of the 16S rRNA gene confirmed the identity of the isolates as Campylobacter jejuni with sequence identity of at least 99.6 percent against reference sequences, and phylogenetic analysis placed the Yemeni isolates in clusters closely related to established reference strains. This matters for two reasons. First, phenotypic identification of Campylobacter can be ambiguous, and molecular confirmation guards against misclassification that would distort prevalence and resistance statistics. Second, phylogenetic context allows researchers to begin tracing how strains circulate between animals, food, water and humans, a prerequisite for understanding transmission dynamics in a setting where such data have been almost entirely absent. The authors note that future work should employ advanced techniques to detect the antibiotic resistance genes themselves, and should use specialized genetic primers capable of differentiating between Campylobacter subspecies, alongside larger samples drawn from more diverse populations and methods such as multi-locus sequence typing and whole-genome sequencing.

The study was conducted with formal ethical oversight, receiving approval from the Research Ethics Review Committee at the Faculty of Science, Sana’a University under number BM-02-23, dated 11 April 2021, and complying with Yemeni Public Health Law No. 4 of 2009 and the Declaration of Helsinki. Because all participants were children under five, written informed consent was obtained from their parents or legal guardians before enrollment. The research team spanned several Yemeni institutions, including Sana’a University’s Faculty of Science, Hajjah University, Al-Razi University, Al Mahwit University and Ibb University, a collaboration that reflects both the country’s scientific capacity and the logistical challenges of conducting microbiological research amid prolonged instability. The work was published open access, with the article accepted on 21 September 2026 and published on 24 September 2026.

For global health observers, the Sana’a study is a reminder that antimicrobial resistance is not a problem confined to wealthy nations with dense surveillance networks; it evolves wherever antibiotics are used, and it is most dangerous precisely where the capacity to detect it is weakest. The authors close with a call that is as much public health as laboratory science: raising community awareness of hand hygiene after contact with animals, promoting safe food handling, encouraging water treatment, and curbing imprudent antibiotic use. Those measures, combined with expanded epidemiological studies and molecular surveillance, would give Yemeni clinicians something they currently lack, namely an evidence base for treating the youngest and most vulnerable patients with the right drug the first time, while slowing the further march of resistance in a pathogen that thrives at the intersection of animals, water, food and childhood.

Subject of Research: Molecular detection and antimicrobial resistance of Campylobacter jejuni in children with diarrhea in Sana'a City, Yemen

Article Title: Molecular detection and antibiotic susceptibility patterns of Campylobacter jejuni isolated from children under five years in Sana’a City, Yemen

Article References: Molecular detection and antibiotic susceptibility patterns of Campylobacter jejuni isolated from children under five years in Sana’a City, Yemen. (n.d.). https://doi.org/10.1186/s12879-026-14520-y

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14520-y

Keywords: Campylobacter jejuni, diarrhea, children under five, antimicrobial resistance, 16S rRNA sequencing, Yemen, Sana'a City, macrolide resistance, foodborne pathogens, public health, phylogenetic analysis, water and food safety

The surveillance programme was deliberately time-limited, running from January to April 2024, and was designed to capture both the severe end of the disease spectrum and the milder cases circulating in the wider population. Paediatric samples that tested positive for M. pneumoniae were collected from participating hospitals as well as from Singapore’s community acute respiratory infection surveillance programme. All of these specimens were funnelled to the National Public Health Laboratory, where they underwent genotypic testing for macrolide resistance. This dual sampling strategy matters scientifically: hospital-based studies alone tend to overestimate the clinical severity of resistant infections, because resistant cases that fail first-line therapy are more likely to end up in hospital in the first place. By including community cases, the Singapore team could compare resistant and susceptible strains across the full range of illness, from children treated as outpatients to those requiring admission.

In total, 412 M. pneumoniae cases were successfully genotyped and included in the analysis, comprising 275 hospitalised children and 137 community cases, all aged between zero and sixteen years. Among the hospitalised group, 16.7 percent carried the resistance mutation, with a 95 percent confidence interval of 12.5 to 21.7 percent. In the community, the figure was slightly higher at 19.7 percent, with a confidence interval of 13.4 to 27.4 percent. The mutation in question, A2063G, is a single nucleotide substitution in the 23S ribosomal RNA gene. This is the molecular heart of the macrolide mechanism: macrolides work by binding to the 23S rRNA component of the bacterial ribosome’s 50S subunit, physically blocking the exit tunnel through which the growing protein chain must pass. A single base change at position 2063 alters the conformation of the binding pocket, dramatically reducing drug affinity and rendering the antibiotic largely ineffective, while leaving the bacterium otherwise intact and transmissible.

The genetic basis of this resistance explains both its rapid spread and its persistence. Because resistance arises from a point mutation rather than the acquisition of a foreign resistance gene, it can emerge and fix within circulating lineages under antibiotic pressure, and it is passed vertically to daughter cells during replication. Unlike some resistance mechanisms that carry fitness costs, MRMP strains have demonstrated in multiple Asian settings that they can sustain themselves in the population over years. Countries such as China, Japan, and South Korea have reported resistance rates exceeding 80 to 90 percent in some paediatric cohorts, which makes Singapore’s figure of roughly 17 to 20 percent comparatively moderate. The study’s authors suggest that this intermediate level may reflect Singapore’s position at an earlier stage of the same epidemiological trajectory, underscoring the value of periodic surveillance to detect any upward shift before it becomes entrenched.

Perhaps the most clinically consequential finding concerns what resistance actually does to children who are infected. In adjusted statistical analyses, children with MRMP had a higher likelihood of recent overseas travel, with an odds ratio of 2.28 and a confidence interval of 1.09 to 4.77, hinting at imported strains or travel-linked transmission. More tangibly, resistant infections were associated with a longer duration of fever, averaging an additional 2.24 days compared with macrolide-susceptible cases, a difference that was statistically significant at p less than 0.01. Hospitalisation was also prolonged, by an average of 0.94 days, with a p value of 0.01. These differences are biologically coherent: if the first-line antibiotic cannot inhibit the bacterium, the child’s immune system must do the work alone, prolonging symptomatic illness and extending the time needed for recovery, while clinicians may cycle through additional treatments or investigations before the infection is brought under control.

Crucially, however, the study found no evidence that resistance translated into greater disease severity beyond these temporal measures. The researchers detected no differences between hospitalised MRMP and macrolide-susceptible cases in age, ethnicity, comorbidities, symptomatology, the presence of co-infections, care acuity, or mortality. All MRMP inpatients were discharged well. This pattern is consistent with the prevailing understanding of M. pneumoniae pathogenesis, in which much of the lung damage is driven by the host’s inflammatory response rather than by direct bacterial destruction of tissue. A resistant strain may persist longer and provoke a more prolonged inflammatory course, but it does not appear to be intrinsically more virulent. For clinicians and parents alike, the practical message is that resistant infections tend to be longer and more inconvenient rather than more dangerous, at least at the current prevalence.

The demographic and clinical equivalence between resistant and susceptible cases also carries an important diagnostic implication. Because children with MRMP cannot be distinguished from those with susceptible infections on the basis of symptoms, age, or risk factors, clinicians cannot identify resistance at the bedside. In settings where resistance rates are high, this has driven interest in rapid molecular resistance testing, which can detect the 23S rRNA mutations directly from respiratory specimens within hours. The Singapore findings, showing that resistance is present at a meaningful but not overwhelming frequency, suggest that universal resistance testing is not yet an urgent necessity locally, but the study provides exactly the kind of baseline prevalence data that health authorities need to decide when such testing would become cost-effective. The authors note that the findings do not indicate an immediate need to alter current local empirical treatment recommendations, although they caution that further research is needed to evaluate treatment effectiveness in MRMP infections specifically.

The association with recent overseas travel adds a layer of epidemiological interest. With an odds ratio above two, travel history emerged as the only demographic or epidemiological factor independently linked to resistant infection in the adjusted analysis. This fits with the broader geography of macrolide resistance, which is far more established in many neighbouring Asian countries than in Singapore itself. Cross-border movement of both people and microbial lineages is a well-documented driver of antimicrobial resistance dissemination, and the finding suggests that imported strains may be seeding local circulation. It also illustrates why resistance surveillance is inherently a regional, and indeed global, undertaking: a country’s resistance profile is shaped not only by its own antibiotic prescribing practices but also by those of its neighbours and by the volume of travel connecting them.

The study was conducted under Singapore’s national infectious disease surveillance framework, operating under the provisions of the Infectious Diseases Act, which meant that statutory public health surveillance provisions governed the work and institutional review board approval was not required. The research received no specific external funding, and the analytical work drew on the bacteriology team at the National Public Health Laboratory for sample processing and downstream analysis of the respiratory specimens. The breadth of institutional involvement, spanning the Communicable Diseases Agency, the National Centre for Infectious Diseases, the Saw Swee Hock School of Public Health, National University Hospital, and KK Women’s and Children’s Hospital, reflects the multicentre design that gives the prevalence estimates their robustness across both hospital and community settings.

The authors conclude that periodic surveillance and responsible antimicrobial stewardship are crucial to mitigating rising resistance, and their data support a measured rather than alarmist response. Macrolides remain an appropriate first-line empirical choice for paediatric M. pneumoniae infections in Singapore for now, since the large majority of circulating strains remain susceptible and no severity penalty from resistance has been demonstrated. But the study also documents that resistance has firmly arrived, that it prolongs fever and hospital stays, and that it is associated with travel-linked introduction. As M. pneumoniae continues its cyclical epidemics around the world, and as neighbouring countries grapple with far higher resistance levels, the Singapore experience offers a template for how a well-organised surveillance system can track a resistance problem early, quantify its clinical impact honestly, and buy time for stewardship measures to work before the therapeutic calculus fundamentally changes.

Subject of Research: Macrolide-resistant Mycoplasma pneumoniae epidemiology and clinical impact in Singaporean children

Article Title: Epidemiology and clinical impact of macrolide-resistant Mycoplasma pneumoniae in Singapore – findings from a multicentre surveillance programme

Article References: Keng, B., Lee, J. G. J., Mah, T. K. L., Cheng, S., Ho, C., Goh, A., Khamis, N. H., Khong, W. X., Chae, S.-R., Cui, L., Cho, S. S. L., Lin, R. T. P., Tee, N., Thoon, K. C., Yung, C. F., Li, J., Maiwald, M., Loo, L. H., Yelen, … Said, Z. (2026). Epidemiology and clinical impact of macrolide-resistant Mycoplasma pneumoniae in Singapore – findings from a multicentre surveillance programme. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14346-8

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14346-8

Keywords: Mycoplasma pneumoniae, macrolide resistance, antimicrobial resistance, surveillance, paediatrics, community-acquired pneumonia, A2063G mutation, Singapore, epidemiology, public health, antibiotic stewardship, BMC Infectious Diseases

The research team enrolled 206 pediatric patients diagnosed with mycoplasma pneumoniae pneumonia and compared their peripheral blood immune and inflammatory parameters across clinically defined subgroups, distinguishing macrolide-sensitive cases from severe disease. The comparisons revealed a clear inflammatory gradient. Children with severe mycoplasma pneumonia displayed significantly elevated white blood cell counts and markedly higher circulating levels of interleukin-6, a central pro-inflammatory cytokine that drives acute-phase responses and is often used as a marker of systemic inflammation. At the same time, these severe cases showed reduced proportions of monocytes, a shift that suggests alterations in innate immune cell dynamics as the disease escalates. Taken together, these findings confirm that severe pediatric mycoplasma pneumonia is accompanied by heightened systemic inflammation, providing clinicians with measurable correlates of disease severity that go beyond symptoms and imaging.

While the blood-based immune markers painted a picture of generalized inflammation, the heart of the study lay in its analysis of the T cell receptor beta chain, specifically the complementarity-determining region 3, or CDR3. This hypervariable loop sits at the very tip of the T cell receptor and makes direct contact with peptide antigens presented by major histocompatibility complex molecules. Because the CDR3 sequence is generated through a stochastic process of V, D and J gene segment recombination, joined by random nucleotide trimming and insertion at the junctions, each naive T cell carries a essentially unique CDR3 signature. When a pathogen invades, the handful of T cells whose receptors happen to recognize its antigens undergo clonal expansion, multiplying into large populations of identical sequences that can be detected by sequencing the repertoire. The composition of these expanded clones therefore serves as a molecular record of the antigenic encounters the immune system has experienced.

To capture this record, the researchers performed TCR beta CDR3 repertoire sequencing on peripheral blood samples from eight children with mycoplasma pneumoniae pneumonia and nine age-matched healthy controls. Although the sequencing cohort was modest in size, the bioinformatic analysis was comprehensive, examining repertoire clonality, diversity indices, V and J gene segment usage, CDR3 length distributions, recombination characteristics, and the presence of disease-associated high-frequency or shared clonotypes. The results showed that children with mycoplasma pneumonia had measurably reduced CDR3 diversity compared with healthy controls, a contraction of the overall repertoire that is consistent with a strong antigen-driven response in which a limited number of pathogen-specific clones expand and crowd out the diverse background of bystander T cells.

The clonal architecture itself was also transformed. In healthy individuals, the T cell pool is dominated by a vast number of small, rare clones, with only a sparse scattering of expanded sequences. In the mycoplasma pneumonia patients, the researchers observed a shift toward more medium and large clones, indicating that a substantial fraction of the circulating T cell population had been recruited into antigen-driven expansion. This oligoclonal skewing is a hallmark of active infection and mirrors patterns previously documented in viral infections and other inflammatory lung diseases. The degree of clonal expansion, quantified through measures of clonality, could in principle serve as a quantitative readout of the intensity of the adaptive immune response, potentially helping clinicians distinguish children mounting an effective response from those at risk of immunopathology.

Beyond clonality, the study uncovered striking differences in the genetic mechanics of receptor generation. The mycoplasma pneumonia group showed significant alterations in the usage frequencies of individual TRBV and TRBJ gene segments, the variable and joining elements that form the framework of the beta chain receptor. Certain V-J pairing combinations were overrepresented or underrepresented relative to controls, suggesting that the antigenic landscape presented by mycoplasma pneumoniae selects for receptors built from particular gene segments. The patients also exhibited increased CDR3 lengths, altered amino acid composition within the hypervariable loop, and enhanced V(D)J trimming and nucleotide insertion activity at the recombination junctions. These features imply that the receptors expanded during infection tend to be longer and more compositionally distinctive than average, a pattern that may reflect the structural requirements of recognizing mycoplasma-derived peptides or, alternatively, the recruitment of T cells activated by molecular mimicry.

Perhaps the most intriguing discovery emerged from the search for pathogen-associated clonotypes. The team identified several putative mycoplasma-associated CDR3 sequences that were either present at high frequency in patients or shared across multiple individuals, suggesting convergent recognition of common mycoplasma antigens. Remarkably, some of these expanded clones showed potential cross-reactivity with respiratory viruses, including influenza and Epstein-Barr virus. This observation carries significant immunological weight. Cross-reactive T cells, activated by one pathogen but capable of recognizing structurally similar epitopes from another, are increasingly appreciated as important players in heterologous immunity, the phenomenon by which prior infections shape responses to new ones. In the context of pediatric pneumonia, such cross-reactive expansions could influence disease severity, either by accelerating viral clearance or by contributing to the immune-mediated lung damage seen in severe mycoplasma cases.

The identification of candidate immune signatures also opens a practical avenue for clinical translation. If the disease-associated clonotypes and repertoire features documented here can be validated in larger cohorts, they could form the basis of diagnostic or prognostic tools. A sequencing-based assay that detects mycoplasma-associated T cell expansions might help confirm infection in cases where culture and serology are inconclusive, since mycoplasma is notoriously difficult to grow in the laboratory and antibody responses can be delayed or unreliable in young children. Repertoire clonality measures might additionally serve as biomarkers for monitoring host immune status over the course of treatment, flagging patients whose inflammatory trajectory is worsening before clinical deterioration becomes obvious. The authors suggest that these repertoire characteristics may reflect potential biomarkers for monitoring host immune status or infection-associated T cell responses in pediatric mycoplasma pneumonia.

Several caveats temper the immediate applicability of these findings. The sequencing arm of the study included only eight patients and nine controls, a sample size sufficient for generating hypotheses but insufficient for establishing robust clinical biomarkers. Longitudinal sampling, which would track how the repertoire evolves during infection and recovery, was not performed, and the cross-reactivity assignments to influenza and Epstein-Barr virus remain putative pending functional validation with antigen-specific stimulation assays. Future studies will need to expand patient numbers, incorporate follow-up time points, and pair repertoire data with antigen-specific T cell functional testing to confirm which clonotypes genuinely recognize mycoplasma antigens and which are bystanders or cross-reactive responders.

Nevertheless, the study represents a meaningful step toward bringing immune repertoire sequencing out of the research laboratory and into pediatric infectious disease medicine. By demonstrating that mycoplasma pneumoniae leaves a detectable and characteristic imprint on the TCR beta CDR3 landscape of infected children, the work establishes a framework for understanding the immunological heterogeneity that underlies the variable clinical course of this common infection. As sequencing costs continue to fall and analytical pipelines mature, the kind of repertoire profiling demonstrated here could eventually complement conventional laboratory tests, giving clinicians a dynamic view of the adaptive immune response as it unfolds. For a pathogen that has repeatedly proven difficult to detect and even more difficult to anticipate in terms of severity, the T cell receptor repertoire may prove to be one of the most informative windows yet into how the body fights back.

Subject of Research: T cell receptor repertoire changes in pediatric Mycoplasma pneumoniae pneumonia

Article Title: TCR β CDR3 repertoire profiling identifies pathogen-associated clonal expansions and candidate immune signatures in pediatric Mycoplasma pneumoniae pneumonia

Article References: Yuan, Y., Hui, L., Zhang, X., Liu, X., Yang, C., Xu, Y., Yao, X., Chen, Y., & Li, J. (2026). TCR β CDR3 repertoire profiling identifies pathogen-associated clonal expansions and candidate immune signatures in pediatric Mycoplasma pneumoniae pneumonia. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08992-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08992-4

Keywords: Mycoplasma pneumoniae, pediatric pneumonia, TCR repertoire, CDR3 diversity, high-throughput sequencing, T cell receptor, clonal expansion, interleukin-6, immune biomarkers, cross-reactivity, macrolide resistance, Journal of Translational Medicine

The biological target of the new assay is domain V of the 23S rRNA gene, the region of the bacterial ribosome where macrolides normally bind to halt protein synthesis. Point mutations at nucleotide positions 2063 and 2064, most commonly the substitutions A2063G and A2064G, alter the architecture of the macrolide binding pocket so that the drug can no longer attach effectively. These two adjacent sites account for the overwhelming majority of macrolide-resistant M. pneumoniae infections worldwide, and distinguishing between them matters because the prevalence and clinical behavior of each genotype can differ by geography and outbreak context. Conventional detection relies on Sanger sequencing of amplified DNA, a reliable but slow and labor-intensive process that requires expensive equipment, multiple handling steps, and expert interpretation. Real-time PCR approaches exist, but many depend on melting-curve analysis, which can be technically demanding when the mutations of interest sit only a single nucleotide apart.

The Korean team, led by Hyeonseek Park and Minhee Kang of the Biomedical Engineering Research Center at Samsung Medical Center’s Smart Healthcare Research Institute, together with Sun Ae Yun, Tae Yeul Kim, and Hee Jae Huh, tackled this discrimination problem with minor groove binding probes. MGB probes are short DNA oligonucleotides conjugated to a small molecule that wedges into the minor groove of the DNA double helix, dramatically stabilizing the probe-target duplex. This added stabilization permits the use of very short probes, and short probes are exquisitely sensitive to even a single mismatched base. By designing position-specific MGB probes that selectively bind the mutant sequences at positions 2063 and 2064, the researchers created a multiplex assay in which each genotype lights up with its own fluorescence signature, allowing accurate discrimination of point mutations at the two adjacent nucleotide sites within the same reaction tube.

Achieving clean separation between genotype-specific fluorescence signals required careful optimization of the reaction conditions. One of the key findings reported by the team was that decreasing primer concentrations improved probe-target discrimination, a counterintuitive adjustment that reduces the amplification pressure favoring imperfect probe binding and sharpens the boundary between true signal and background. With the optimized chemistry, the assay assigns genotypes purely from endpoint fluorescence readings, eliminating the need for melting-curve analysis altogether. That simplification matters operationally: endpoint genotyping reduces the analytical complexity of the run, shortens the time to result, and makes the workflow easier to implement on standard real-time PCR instruments already present in clinical laboratories, without requiring specialized high-resolution melting hardware or bespoke analysis software.

Analytical performance figures reported in the study are striking. The limits of detection were 31.0 copies per milliliter for the wild-type genotype, 27.2 copies per milliliter for A2063G, 43.2 copies per milliliter for A2063C, 39.3 copies per milliliter for A2063T, and 32.7 copies per milliliter for A2064G. These values, all in the low tens of copies per milliliter, indicate that the assay can detect resistance mutations even when the bacterial load in a respiratory specimen is very low, a situation common in later stages of infection or after partial antibiotic treatment. Notably, the assay covers not only the two dominant mutations but also the rarer A2063C and A2063T substitutions, giving it a broader genotypic reach than many existing rapid tests that focus on a single variant.

Specificity is as critical as sensitivity in a genotyping assay intended for clinical decision-making, because a false resistance call could push a clinician toward unnecessary second-line therapy. The researchers evaluated cross-reactivity against a panel of 24 non-target respiratory pathogens, including the bacteria and viruses most likely to co-circulate with M. pneumoniae in patients with pneumonia, and observed no cross-reactivity among any of them. This clean specificity profile reflects the design logic of the MGB probes: because each probe is short and stabilized by the minor groove binder, only a perfect match to the target sequence produces a stable fluorescent signal, while sequences from other organisms or the wild-type allele dissociate and remain dark.

The clinical evaluation used 44 respiratory specimens obtained from 44 patients with suspected M. pneumoniae infection, analyzed under a protocol approved by the Samsung Medical Center Institutional Review Board with the informed consent requirement waived because the study was retrospective and used de-identified leftover specimens. Sanger sequencing, the traditional reference standard, yielded interpretable results for 40 of the 44 specimens, and the new MGB probe-based assay was fully concordant with the sequence-based reference results in all 40 cases. The four specimens that sequencing could not resolve underscore a practical advantage of the rapid assay: low bacterial loads that defeat conventional sequencing can still fall within the detection range of a sensitive probe-based PCR, meaning the genotyping result may be available precisely when sequencing fails.

Against a commercially available real-time PCR assay, the developed method achieved 100 percent overall percent agreement across all 44 specimens, with a 95 percent confidence interval of 92.0 to 100.0 percent and a Cohen’s kappa of 1.00, the statistical ceiling for perfect agreement. While the sample size is modest and larger multi-center validations will be needed before widespread adoption, the combination of perfect concordance with both a sequencing reference and an established commercial assay provides strong initial evidence that the endpoint genotyping approach performs reliably on real clinical material. The study was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare of the Republic of Korea, and by the Future Medicine 2030 Project of the Samsung Medical Center, and the authors declared no competing interests.

The clinical significance of rapid macrolide resistance genotyping is difficult to overstate in regions where resistant strains dominate. In parts of East Asia, the majority of circulating M. pneumoniae isolates carry A2063G or A2064G, meaning that empiric macrolide therapy frequently fails, prolonging fever, extending hospital stays, and increasing transmission. When a laboratory can report within a single working day that a patient’s isolate carries a resistance mutation, physicians can switch promptly to alternatives such as tetracyclines or fluoroquinolones, the latter reserved for older patients because of effects on cartilage development. The authors conclude that the multiplex MGB probe-based PCR assay allows rapid and reliable detection of closely spaced macrolide resistance mutations in M. pneumoniae and could support timely antimicrobial decision-making in clinical settings, a framing that positions the test as a practical stewardship tool rather than a purely research instrument.

More broadly, the study illustrates how probe chemistry refinements can solve a persistent molecular diagnostics challenge: distinguishing mutations that sit immediately adjacent to one another in a short stretch of DNA. Minor groove binding technology has found applications across oncology, virology, and microbiology, but the demonstration that endpoint fluorescence alone, without melting analysis, can resolve two neighboring nucleotide positions in a clinically relevant pathogen offers a template for other resistance genotyping assays, from tuberculosis drug resistance to antiviral mutations. As macrolide-resistant M. pneumoniae continues its geographic spread, tools of this kind, fast, sensitive to a few dozen genome copies, and deployable on existing laboratory instruments, may become an essential part of the diagnostic arsenal that keeps antibiotic choices targeted, effective, and sustainable.

Subject of Research: Rapid endpoint genotyping of macrolide resistance mutations in Mycoplasma pneumoniae using minor groove binding probe PCR

Article Title: Endpoint genotyping of A2063G and A2064G mutations in Mycoplasma pneumoniae

Article References: Park, H., Kang, M., Yun, S. A., Kim, T. Y., & Huh, H. J. (2026). Endpoint genotyping of A2063G and A2064G mutations in Mycoplasma pneumoniae. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14041-3

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14041-3

Keywords: Mycoplasma pneumoniae, macrolide resistance, 23S rRNA, A2063G, A2064G, minor groove binder probe, endpoint genotyping, PCR, antimicrobial resistance, diagnostics, respiratory infection, molecular assay